source
- Vertex reports positive Phase 2b results for inaxaplin in APOL1-mediated kidney diseaseVertex Pharmaceuticals announced positive Phase 2b data for its kidney disease candidate inaxaplin, which targets APOL1-mediated kidney disease (AMKD). The Amplified trial enrolled two cohorts: 2…
- US officials launch probe into falling German drug prices amid EU pharma push for competitivenessUS trade officials held a hearing on Tuesday about a possible investigation into the decline in Germany's payments for pharmaceuticals. Testimony presented arguments both supporting and opposing t…